Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: topol ej. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ; TARGET investigators. Moliterno DJ, et al. Among authors: topol ej. Lancet. 2002 Aug 3;360(9330):355-60. doi: 10.1016/S0140-6736(02)09605-8. Lancet. 2002. PMID: 12241774 Clinical Trial.
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
Mukherjee D, Gurm H, Tang WH, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissinio D, Bode C, Steg G, Lincoff AM, Topol EJ. Mukherjee D, et al. Among authors: topol ej. Am J Cardiol. 2002 Dec 1;90(11):1198-203. doi: 10.1016/s0002-9149(02)02834-5. Am J Cardiol. 2002. PMID: 12450598 Clinical Trial.
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: topol ej. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators. Chan AW, et al. Among authors: topol ej. J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95. doi: 10.1016/s0735-1097(03)00944-6. J Am Coll Cardiol. 2003. PMID: 14522478 Free article. Clinical Trial.
1,219 results